|
|
Post by myocat on Feb 11, 2016 10:27:07 GMT -5
Asking a child's endo about a drug that's not approved for children?... Not surprisingly he's never heard of it and would be nuts to prescribe it. Doctors get sued for patients walking into the office and stubbing their toe (in this country). Not a situation that's conductive for proactive medicine. Pediatric Study ongoing... Teens are getting Afrezza off label. That's why Matt follows me on Twitter. Best thing that ever happened to them! My point was to know if he is aware of Afrezza. We will be travelling out of the country soon and I hate to see my child has to carry the pens for humalog and lantus. |
|
|
|
Post by kball on Feb 11, 2016 10:36:34 GMT -5
I'm sure most have heard this story. I've been saying over and over..where are the reps!!! Temecula CA. The doc that owns the building I work in ( gym ) has 35 doc's under him at 3 different places in town. Not one rep showed up until Dec. dropped off some flyers. He had not heard about Afrezza except from me. He said no talk in the medical community at all. He is very well known! Doctor's with out borders. On the BOD at 3 hospitals. ( Loma Linda). He can't believe I've been in this stock for so long but thinks Afrezza will be huge!! ( I told him about the teens). For the new members that don't know. I have a client, (I'm a personal trainer, ) that has two kids on Afrezza. 15 and 17. They got scripts off label. There dad is a MNKD long. I'm around a lot of people. Over weight, some T2's. No one had heard! Sanofi made "substantial efforts." You didnt get the memo?! LOL. Am I missing something about wanting Mannkind management to counter this false narrative? I mean, are Matt and Hakan playing a 3-D chess game that my simple mind cannot grasp? Why doesnt management aggressively stick up for THEIR/OUR company like an Elon Musk does? Sigh. Well, a bad in San Diego is a good day anywhere else, what I tell myself. So theres that.  SportsGroupies! |
|
|
|
Post by liane on Feb 11, 2016 10:40:39 GMT -5
Not surprisingly he's never heard of it and would be nuts to prescribe it. Doctors get sued for patients walking into the office and stubbing their toe (in this country). Not a situation that's conductive for proactive medicine. Many, many drugs have not been studied in the pediatric population. It is quite common to prescribe "off-label" for them. |
|
|
|
Post by mnholdem on Feb 11, 2016 13:06:54 GMT -5
I'm sure most have heard this story. I've been saying over and over..where are the reps!!! Temecula CA. [clipped] I'm around a lot of people. Over weight, some T2's. No one had heard! Sanofi made "substantial efforts." You didnt get the memo?! LOL. Am I missing something about wanting Mannkind management to counter this false narrative? I mean, are Matt and Hakan playing a 3-D chess game that my simple mind cannot grasp? Why doesnt management aggressively stick up for THEIR/OUR company like an Elon Musk does? Sigh. Well, a bad in San Diego is a good day anywhere else, what I tell myself. So theres that. The unfortunate truth is that MannKind Corporation cannot expose anything that Sanofi did or didn't do in regards to Afrezza without risking committing a breach of the Agreement, which expressly forbids MannKind disclosing any of Sanofi's activities related to development, marketing and/or sales of Afrezza without Sanofi's written permission.
Until Afrezza is officially transferred back to MannKind, there is little Matt can say or print to publicly dispute Sanofi's statements. With that Agreement, Sanofi has effectively gagged MannKind for over a year. It makes me wonder if MannKind's legal counsel (Thompsen) was negligent and did not make Al Mann aware of this.
If Al was made aware, then he trusted Sanofi much more than he should have. If he wasn't made aware, then Thompsen should be fired.
|
|
|
|
Post by dreamboatcruise on Feb 11, 2016 14:10:01 GMT -5
Sanofi made "substantial efforts." You didnt get the memo?! LOL. Am I missing something about wanting Mannkind management to counter this false narrative? I mean, are Matt and Hakan playing a 3-D chess game that my simple mind cannot grasp? Why doesnt management aggressively stick up for THEIR/OUR company like an Elon Musk does? Sigh. Well, a bad in San Diego is a good day anywhere else, what I tell myself. So theres that. No chess... no Hakan. |
|
|
|
Post by suebeeee1 on Feb 12, 2016 9:34:01 GMT -5
Wouldn't it be nice to see Afrezza close above $1 today? Crush (at least) a small group of shorts? Sigh...its not going to happen unless Wall Street says so.....
|
|
|
|
Post by patten1962 on Feb 12, 2016 19:39:46 GMT -5
Wouldn't it be nice to see Afrezza close above $1 today? Crush (at least) a small group of shorts? Sigh...its not going to happen unless Wall Street says so..... I think mannkind stack will climb slow until April 5th. Only thing that may change things is if we see institutions holding strong. If they are stock will climb quick. Thoughts? |
|
|
|
Post by dreamboatcruise on Feb 12, 2016 19:56:05 GMT -5
Wouldn't it be nice to see Afrezza close above $1 today? Crush (at least) a small group of shorts? Sigh...its not going to happen unless Wall Street says so..... The analogy being that the shorts having just eaten an amazing seven course dinner are going to be crushed when the after dinner cappuccino has an insufficient amount of foam  |
|
|
|
Post by suebeeee1 on Feb 13, 2016 12:21:37 GMT -5
Wouldn't it be nice to see Afrezza close above $1 today? Crush (at least) a small group of shorts? Sigh...its not going to happen unless Wall Street says so..... The analogy being that the shorts having just eaten an amazing seven course dinner are going to be crushed when the after dinner cappuccino has an insufficient amount of foam I have no illusions that the shorts are going to be overall losers. I just want some momentary hurt. Didn't get it yesterday. Almost...but no cigar! |
|
|
|
Post by patten1962 on Feb 16, 2016 21:14:26 GMT -5
The analogy being that the shorts having just eaten an amazing seven course dinner are going to be crushed when the after dinner cappuccino has an insufficient amount of foam I have no illusions that the shorts are going to be overall losers. I just want some momentary hurt. Didn't get it yesterday. Almost...but no cigar! The fact that the institutions are still holding I would think that alone would drive the stock price up. |
|
|
|
Daily PPS
Feb 16, 2016 21:19:51 GMT -5
via mobile
Post by vestful on Feb 16, 2016 21:19:51 GMT -5
I have no illusions that the shorts are going to be overall losers. I just want some momentary hurt. Didn't get it yesterday. Almost...but no cigar! The fact that the institutions are still holding I would think that alone would drive the stock price up. Do you have privilege to institional holdings without a quarter delay? |
|
|
|
Daily PPS
Feb 16, 2016 21:41:59 GMT -5
via mobile
Post by patten1962 on Feb 16, 2016 21:41:59 GMT -5
The fact that the institutions are still holding I would think that alone would drive the stock price up. Do you have privilege to institional holdings without a quarter delay? Maybe I am wrong but it was updated today on Nasdaq. Please correct me if I am wrong! |
|
|
|
Daily PPS
Feb 16, 2016 22:01:48 GMT -5
via mobile
Post by kc on Feb 16, 2016 22:01:48 GMT -5
I have no illusions that the shorts are going to be overall losers. I just want some momentary hurt. Didn't get it yesterday. Almost...but no cigar! The fact that the institutions are still holding I would think that alone would drive the stock price up. We have lost some institutional support because we had been up to about 27% at one time in December |
|
|
|
Post by benyiju on Feb 16, 2016 22:14:09 GMT -5
Do you have privilege to institional holdings without a quarter delay? Maybe I am wrong but it was updated today on Nasdaq. Please correct me if I am wrong! You are wrong Patten, and it has been pointed out to you before. Probably more than once. These updates don't cover current quarter, so they don't show what happened after Sanofi dumped Afrezza, the new CEO left us standing at the altar, and MNKD became a penny stock. |
|
|
|
Post by myocat on Feb 16, 2016 22:43:47 GMT -5
Another smear job.... Did MNKD really drop??? "All data provided by QuoteMedia and was accurate as of 4:30PM ET." MannKind Corporation (MNKD) Drops 5.5% on February 16 Equities Staff | Tuesday, 16 February 2016 16:01 (EST) MannKind Corporation (MNKD) was one of the Russell 2000's biggest losers for Tuesday February 16 as the stock slid 5.5% to $0.93, a loss of $-0.0541 per share. Starting at an opening price of $1.00 a share, the stock traded between $0.93 and $1.01 over the course of the trading day. Volume was 2.89 million shares over 5,194 trades, against an average daily volume of 7.26 million shares and a total float of 409.49 million. The losses send MannKind Corporation down to a market cap of $380.82 million. In the last year, MannKind Corporation has traded between $7.32 and $0.64, and its 50-day SMA is currently $1.20 and 200-day SMA is $3.38. MannKind Corp is a development stage company engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes. MannKind Corporation is based out of Valencia, CA and has some 287 employees. Its CEO is Matthew J. Pfeffer. For a complete fundamental analysis analysis of MannKind Corporation, check out Equities.com’s Stock Valuation Analysis report for MNKD. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index. Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole. For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section. All data provided by QuoteMedia and was accurate as of 4:30PM ET. DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: www.equities.com/disclaimerwww.equities.com/news/mannkind-corporation-mnkd-drops-5-5-on-february-16 |
|
